Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ludovic, Ménard"'
Autor:
Darren A.E. Cross, Philip C. Mack, David R. Gandara, James G. Keck, Rebekah A. Burich, Daniel P. Vang, Mingshan Cheng, Darren McKerrecher, M. Raymond V. Finlay, Richard A. Ward, Daniel J. O'Neill, Maria Emanuela Cuomo, Ludovic Ménard, Anna D. Staniszewska, Jonathan P. Orme, Jonathan W. Riess, Matthew J. Martin, Nicolas Floc'h
Supplementary figure 1: Generation of H2073 ASV and H2073 SVD. Supplementary figure 2: H2073 parental and Ex20Ins are dependent on EGFR for survival in vitro. Supplementary figure 3: Effect of TKI on the Sytox Proliferation of H2073 wt, H2073-SVD and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f56c0e6f4081d567187d483f6041777
https://doi.org/10.1158/1535-7163.22505797
https://doi.org/10.1158/1535-7163.22505797
Autor:
Darren A.E. Cross, Philip C. Mack, David R. Gandara, James G. Keck, Rebekah A. Burich, Daniel P. Vang, Mingshan Cheng, Darren McKerrecher, M. Raymond V. Finlay, Richard A. Ward, Daniel J. O'Neill, Maria Emanuela Cuomo, Ludovic Ménard, Anna D. Staniszewska, Jonathan P. Orme, Jonathan W. Riess, Matthew J. Martin, Nicolas Floc'h
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de56d8339b2fdb08f9c7f6a79f45f94b
https://doi.org/10.1158/1535-7163.c.6538186.v1
https://doi.org/10.1158/1535-7163.c.6538186.v1
Clathrin inhibition induces mutant-EGFR degradation but not WT EGFR and TfnR degradation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2892bd66893c232b3f6fbc9cce32bcc7
https://doi.org/10.1158/0008-5472.22417217
https://doi.org/10.1158/0008-5472.22417217
Tyrosine kinase inhibitors (TKI) targeting mutant EGFR in non–small cell lung cancer (NSCLC) have been successful to control cancer growth, but acquired resistance inevitably occurs, including mutations directly on EGFR, for example, T790M and C797
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad4d2f7ccb2167a79ce7cbf00ddf357
https://doi.org/10.1158/0008-5472.c.6509777
https://doi.org/10.1158/0008-5472.c.6509777
Autor:
Rachel Barrow-McGee, Naoki Kishi, Carine Joffre, Ludovic Ménard, Alexia Hervieu, Bakhouche A. Bakhouche, Alejandro J. Noval, Anja Mai, Camilo Guzmán, Luisa Robbez-Masson, Xavier Iturrioz, James Hulit, Caroline H. Brennan, Ian R. Hart, Peter J. Parker, Johanna Ivaska, Stéphanie Kermorgant
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-18 (2016)
Cooperative signalling between receptor tyrosine kinases (RTKs) and integrins is thought to occur at the cell surface. Here the authors show that β1 integrin influences signalling of an RTK, c-Met, from a novel intracellular compartment they call au
Externí odkaz:
https://doaj.org/article/452ea8b8d9b2466d9eb39259519916df
Autor:
Rachel Barrow-McGee, Naoki Kishi, Carine Joffre, Ludovic Ménard, Alexia Hervieu, Bakhouche A. Bakhouche, Alejandro J. Noval, Anja Mai, Camilo Guzmán, Luisa Robbez-Masson, Xavier Iturrioz, James Hulit, Caroline H. Brennan, Ian R. Hart, Peter J. Parker, Johanna Ivaska, Stéphanie Kermorgant
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-1 (2016)
Nature Communications 7 Article number:11942 (2016); Published 23 June 2016; Updated 21 July 2016 The original version of this Article contained an error in the spelling of the author Luisa Robbez-Masson, which was incorrectly given as Luisa Robert-M
Externí odkaz:
https://doaj.org/article/f865856d240348fba98e76cb68ca0162
Autor:
Carine Joffre, Paul A. Clarke, Chi Zhang, Sara Farrah Heuss, Alexia Hervieu, Stéphanie Kermorgant, Ludovic Ménard, Rachel Barrow-McGee
Publikováno v:
Sci Signal
Receptor tyrosine kinases (RTKs) are often overexpressed or mutated in cancers and drive tumor growth and metastasis. In the current model of RTK signaling, including that of the RTK MET, downstream phosphoinositide 3-kinase (PI3K) mediates both cell
Publikováno v:
Cancer Research. 78:3267-3279
Tyrosine kinase inhibitors (TKI) targeting mutant EGFR in non–small cell lung cancer (NSCLC) have been successful to control cancer growth, but acquired resistance inevitably occurs, including mutations directly on EGFR, for example, T790M and C797
Autor:
Markus Ollert, Malina Xiao, Martyna Szpakowska, Bassam Janji, Ludovic Ménard, Andy Chevigné, Muhammad Zaeem Noman, Manon Bosseler, Guy Berchem
Publikováno v:
Critical Reviews™ in Oncogenesis. 23:321-332
Autophagy is a quality control process executed at the basal level in almost all cell types. However, in cancer cells, autophagy is activated by several stimuli, including hypoxia. Depending on tumor type, stage, and genetic context, autophagy is a d
Autor:
Daniel P. Vang, Anna Staniszewska, Matthew J. Martin, James G. Keck, Darren Cross, Jonathan W. Riess, Mingshan Cheng, Maria Emanuela Cuomo, M. Raymond V. Finlay, Ludovic Ménard, Rebekah A. Burich, Darren Mckerrecher, Nicolas Floc'h, David R. Gandara, Jonathan P. Orme, Richard A. Ward, Daniel O'Neill, Philip C. Mack
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e66e09f91e4ee9b80623cfb56bb2e9
https://europepmc.org/articles/PMC5932243/
https://europepmc.org/articles/PMC5932243/